Lexicon Pharmaceuticals (NASDAQ:LXRX) Director Buys $148,000.00 in Stock

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Director Raymond Debbane bought 100,000 shares of the firm’s stock in a transaction that occurred on Friday, February 20th. The shares were acquired at an average price of $1.48 per share, with a total value of $148,000.00. Following the purchase, the director owned 1,804,186 shares in the company, valued at $2,670,195.28. This trade represents a 5.87% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Raymond Debbane also recently made the following trade(s):

• On Monday, February 23rd, Raymond Debbane bought 100,000 shares of Lexicon Pharmaceuticals stock. The stock was purchased at an average price of $1.47 per share, for a total transaction of $147,000.00.
• On Thursday, February 19th, Raymond Debbane purchased 50,000 shares of Lexicon Pharmaceuticals stock. The shares were acquired at an average price of $1.44 per share, with a total value of $72,000.00.

Lexicon Pharmaceuticals Stock Up 1.4%

Lexicon Pharmaceuticals stock opened at $1.50 on Thursday. The stock has a market capitalization of $545.21 million, a PE ratio of -7.89 and a beta of 0.98. The company has a 50 day moving average of $1.31 and a 200-day moving average of $1.31. Lexicon Pharmaceuticals, Inc. has a twelve month low of $0.28 and a twelve month high of $1.83. The company has a quick ratio of 5.63, a current ratio of 5.64 and a debt-to-equity ratio of 0.47.

Institutional Trading of Lexicon Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. R Squared Ltd increased its position in shares of Lexicon Pharmaceuticals by 45.3% during the fourth quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock valued at $54,000 after buying an additional 14,530 shares during the period. Savant Capital LLC increased its holdings in Lexicon Pharmaceuticals by 33.2% during the 2nd quarter. Savant Capital LLC now owns 69,578 shares of the biopharmaceutical company’s stock worth $66,000 after acquiring an additional 17,348 shares during the period. Bank of America Corp DE lifted its stake in Lexicon Pharmaceuticals by 80.1% in the 3rd quarter. Bank of America Corp DE now owns 57,804 shares of the biopharmaceutical company’s stock worth $78,000 after purchasing an additional 25,707 shares in the last quarter. Vermillion & White Wealth Management Group LLC raised its position in shares of Lexicon Pharmaceuticals by 400.0% in the third quarter. Vermillion & White Wealth Management Group LLC now owns 32,500 shares of the biopharmaceutical company’s stock worth $44,000 after buying an additional 26,000 shares in the last quarter. Finally, Security National Bank of Sioux City Iowa IA bought a new position in Lexicon Pharmaceuticals in the 4th quarter worth about $31,000. 74.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently commented on LXRX shares. Wall Street Zen lowered Lexicon Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Lexicon Pharmaceuticals in a report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $3.23.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.

The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.